heterogeneous nuclear ribonucleoprotein C pseudogene 10Genealiases: []
Q-omics provides the consensus-scored HNRNPCP10 profile across patient tissues and cancer cell-line models. HNRNPCP10 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in THCA. Among the 18 cancer types available for tumor–normal comparison, HNRNPCP10 is differentially expressed in 2, with the highest sampling consensus in COAD. Additionally, HNRNPCP10 RNA expression shows 5,854 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight THCA, COAD, and STAD as cancer lineages where HNRNPCP10 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HNRNPCP10 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HNRNPCP10 survival associations across molecular data types. HNRNPCP10 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HNRNPCP10 RNA expression–survival associations across cancer types. High HNRNPCP10 expression shows unfavorable associations in LUSC, STAD, KIRP, READ and CESC, but favorable associations in THCA. The THCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .010). Together, the overview and detailed table identify THCA as the clearest survival context for HNRNPCP10 RNA expression.
This table summarizes HNRNPCP10 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for HNRNPCP10. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HNRNPCP10 shows higher tumor expression in COAD and BLCA. The COAD box plot shows higher HNRNPCP10 RNA expression in tumor versus normal tissue (log2 FC = +0.142, t-test p = .010).
This table shows molecular features associated with HNRNPCP10 in patient tissues and cancer cell lines. In patient samples, HNRNPCP10 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
